Experimental Gerontology. Vol 90, April 2017, pg 90-97, https://doi.org/10.1016/j.exger.2017.01.019
Jacqueline A Pettersen
- Cognition of Alzheimer’s patients improved by daily 4,000 IU of vitamin D – RCT Jan 2015
- Reversal of cognitive decline with multitherapy (not monotherapy) – Sept 2014 Omega-3, etc.
Cognitive category starts with the following
Very brief summary of Cognitive decline
Treatment : Vitamin D intervention slows or stops progression
Prevention : Many observational studies - perhaps Vitamin D prevents
Omega-3 both prevents and treats cognition
Wonder the benefits if both Vitamin D AND Omega-3 were to be used
see also Alzheimers-Cognition - Overview
Overview Parkinsons and Vitamin D
Search VitaminDWiki for dementia anywhere in text 1190 items Jan 2019
Overview Schizophrenia and Vitamin D
Search VitaminDWiki for "WHITE MATTER" 53 items as of Jan 2017
37 minute podcast Vitamin D and the brain Vitamin D Council Sept 2014
Includes discussion by Dr. Cannell and Dr. David Llewellyn
• Novel trial of high versus low dose vitamin D3 on multiple cognitive domains
• High dose vitamin D (4000 IU/d) improved nonverbal (visual) memory after 18 weeks.
• 25(OH)D levels < 75 nmol/L at baseline may confer more benefit with supplementation.
Insufficiency of 25-hydroxyvitamin D [25(OH)D] has been associated with dementia and cognitive decline. However, the effects of vitamin D supplementation on cognition are unclear. It was hypothesized that high dose vitamin D3 supplementation would result in enhanced cognitive functioning, particularly among adults whose 25(OH)D levels were insufficient (< 75 nmol/L) at baseline.
Healthy adults (n = 82) from northern British Columbia, Canada (54° north latitude) with baseline 25(OH)D levels ≤ 100 nmol/L were randomized and blinded to High Dose (4000 IU/d) versus Low Dose (400 IU/d) vitamin D3 (cholecalciferol) for 18 weeks. Baseline and follow-up serum 25(OH)D and cognitive performance were assessed and the latter consisted of: Symbol Digit Modalities Test, verbal (phonemic) fluency, digit span, and the CANTAB® computerized battery. Results: There were no significant baseline differences between Low (n = 40) and High (n = 42) dose groups. Serum 25(OH)D increased significantly more in the High Dose (from 67.2 ± 20 to 130.6 ± 26 nmol/L) than the Low Dose group (60.5 ± 22 to 85.9 ± 16 nmol/L), p = 0.0001. Performance improved in the High Dose group on nonverbal (visual) memory, as assessed by the Pattern Recognition Memory task (PRM), from 84.1 ± 14.9 to 88.3 ± 13.2, p = 0.043 (d = 0.3) and Paired Associates Learning Task, (PAL) number of stages completed, from 4.86 ± 0.35 to 4.95 ± 0.22, p = 0.044 (d = 0.5), but not in the Low Dose Group. Mixed effects modeling controlling for age, education, sex and baseline performance revealed that the degree of improvement was comparatively greater in the High Dose Group for these tasks, approaching significance: PRM, p = 0.11 (d = 0.4), PAL, p = 0.058 (d = 0.4). Among those who had insufficient 25(OH)D (< 75 nmol/L) at baseline, the High Dose group (n = 23) improved significantly (p = 0.005, d = 0.7) and to a comparatively greater degree on the PRM (p = 0.025, d = 0.6).
Nonverbal (visual) memory seems to benefit from higher doses of vitamin D supplementation, particularly among those who are insufficient (< 75 nmol/L) at baseline, while verbal memory and other cognitive domains do not. These findings are consistent with recent cross-sectional and longitudinal studies, which have demonstrated significant positive associations between 25(OH)D levels and nonverbal, but not verbal, memory. While our findings require confirmation, they suggest that higher 25(OH)D is particularly important for higher level cognitive functioning, specifically nonverbal (visual) memory, which also utilizes executive functioning processes.
|1265 visitors, last modified 20 Nov, 2017, URL: